The principle of action and consequences of the use of ASD in psoriasis and other dermatological and internal diseases of a person have not been thoroughly studied, so we will dwell on what is included in this tool, and how its producers explain the mechanism of the therapeutic effect of the antiseptic stimulant.
The raw material for obtaining ASD is ordinary meat-and-bone meal (MKM), produced from what remains when processing cattle at meat processing plants. MKM is subjected to high-temperature decomposition (sublimation), and then the sublimate is condensed and divided into fractions - ASD 2 and ASD 3.
All studies of this veterinary drug were carried out on animals in the 50-60s of the last century; As a result, the ability of the ASD to affect metabolism (increasing the rate of development of young animals in poultry and pig breeding), stimulate the central nervous system and the protective forces of sick animals. The drug has become an officially recognized means of veterinary medicine as a biogenic stimulant with antiseptic action, as well as tissue therapy.
According to the instructions, the ASD in psoriasis has an immunobiological effect on the body, accelerating the regenerative processes due to the complex effect of substances entering into its composition that activate the general and tissue metabolism.
By the way, it was possible to obtain a more reliable idea of the composition of the preparation relatively recently due to the newest methods of spectroscopy. The effect of ASD 2 in psoriasis and other diseases, as well as ASD 3 in psoriasis is provided by bactericidal and other properties of the sublimation products of MKM proteins: quaternary ammonium salts; low molecular weight amides; containing sulfur lower aliphatic thiols (mercaptans, giving the drug an abominable smell); methylene compounds; phenol derivatives; choline esters of dicarboxylic acids; pyridine bases; substituted urea and other compounds. And although the pharmacodynamics of most of these substances has not been studied (and is not reflected in the instructions to the drug), the researchers suggest that the alkaline nature of the drug (pH 9.5) plays an important role, thanks to which the metabolism in the tissues is optimized.
It is reported that the SDA has a patent of the Russian Federation for use in the treatment of the consequences of chemotherapy, as well as a patent for the "human variant" of ASD, registered in 2000 as a "means for activation therapy." The regulatory effect of SDA on the production of amino acids, which are necessary for the synthesis of neurotransmitters, is indicated, and thus the drug has a cholinomimetic effect (excites and inhibits the acetylcholine receptors). These conclusions were made back in the 1950s by researchers of the All-Russian Scientific Research Institute of Experimental Veterinary Medicine during experiments conducted on animals.